89bio to Participate in the UBS Global Healthcare Conference

Company Overview - 89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases [3] - The company is headquartered in San Francisco and is dedicated to creating best-in-class treatments for patients lacking optimal options [3] Key Developments - The company will participate in a fireside chat at the UBS Global Healthcare Conference on November 12, 2024, at 12:30 PM EST [1] - Management will also engage in one-on-one investor meetings during the conference [1] Product Pipeline - 89bio is currently in Phase 3 studies for its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [3] - Pegozafermin is a fibroblast growth factor 21 (FGF21) analog utilizing unique glycoPEGylated technology to enhance biological activity through an extended half-life [3]